BioCell Innovations Pte Ltd is a Singapore-based company with the primary objective to bring cell and gene therapy to patients-in-need, offering them effective and personalized treatment options. Through extensive research and development, we have developed a range of cutting-edge technologies and platforms to drive this mission forward. One of our core technological advancements lies in our novel cell manufacture process, which aims to reduce potential adverse events associated with cytokine release syndrome (abbreviated as CRS). CRS is a common side effect of chimeric antigen receptor (CAR)-T cell therapy, leading to varying degrees of toxicity and can be fatal to patients. By coupling this innovative method with in-house developed CAR lentiviral vectors (LVs) such as humanized CD19 CAR LVs, we can minimize the occurrence and severity of CRS while maintaining robust anti-tumour efficacy of CAR-T cells. This will significantly improve patient safety and treatment outcomes. This process sets us apart and positions BioCell Innovations Pte Ltd as a frontrunner in the development of safe and effective cell-based therapies. Furthermore, we have on-going development of in-house CAR constructs for both autologous and allogenic T cells development, and this plan is also facilitated through collaboration with key partners in relevant industries and hospitals.